Payment overview · 2025
General Payments
$711.62
34 reported records · 16 companies
Healthcare provider profile · identity verified
Ricardo E Cuadra, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1144251372
Verified facts
What the public records show
CMS Open Payments records show Ricardo E Cuadra, MD received $711.62 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $149.68 | 21.0% | 11 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $134.35 | 18.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $91.41 | 12.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.44 | 7.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.84 | 5.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.04 | 5.3% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.16 | 3.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.09 | 3.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.89 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.15 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.68 | 3.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.17 | 2.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.85 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.89 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.14 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.84 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $612.62 | 33 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $136.66 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $93.91 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $55.44 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $55.44 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.63 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.35 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.57 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
143 | 33 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 907 | 265 |
| Metformin Hcl | Metformin Hcl | 624 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 595 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 577 | 175 |
| Losartan Potassium | Losartan Potassium | 470 | 145 |
| Lisinopril | Lisinopril | 438 | 132 |
| Omeprazole | Omeprazole | 421 | 178 |
| Gabapentin | Gabapentin | 385 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 351 | 115 |
| Simvastatin | Simvastatin | 335 | 109 |
| Furosemide | Furosemide | 333 | 98 |
| Ibuprofen | Ibuprofen | 331 | 117 |
| Alprazolam | Alprazolam | 324 | 65 |
| Pioglitazone Hcl | Pioglitazone Hcl | 304 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 266 | 68 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 226 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 79 |
| Tramadol Hcl | Tramadol Hcl | 215 | 55 |
| Alendronate Sodium | Alendronate Sodium | 204 | 67 |
| Clonazepam | Clonazepam | 198 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 192 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 187 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 58 |
| Jardiance | Empagliflozin | 147 | 34 |
| Meloxicam | Meloxicam | 145 | 77 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 143 | 82 |
| Eliquis | Apixaban | 143 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 140 | 34 |
| Farxiga | Dapagliflozin Propanediol | 139 | 46 |
| Meclizine Hcl | Meclizine Hcl | 139 | 66 |
| Sertraline Hcl | Sertraline Hcl | 136 | 29 |
| Glimepiride | Glimepiride | 135 | 46 |
| Metformin Hcl Er | Metformin Hcl | 134 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 40 |
| Carvedilol | Carvedilol | 132 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 67 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 130 | 70 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 75 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 126 | 74 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 125 | 93 |
| Finasteride | Finasteride | 125 | 37 |
| Montelukast Sodium | Montelukast Sodium | 124 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 45 |
| Levetiracetam | Levetiracetam | 117 | 14 |
| Memantine Hcl | Memantine Hcl | 116 | 40 |
| Potassium Chloride | Potassium Chloride | 111 | 27 |
| Famotidine | Famotidine | 109 | 32 |
| Azithromycin | Azithromycin | 107 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 24 |
| Trazodone Hcl | Trazodone Hcl | 100 | 44 |
| Hydrocortisone | Hydrocortisone | 99 | 52 |
| Glipizide | Glipizide | 92 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 35 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 91 | 29 |
| Ozempic | Semaglutide | 91 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 44 |
| Divalproex Sodium | Divalproex Sodium | 84 | 12 |
| Nifedipine Er | Nifedipine | 84 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 82 | 64 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 32 |
| Fenofibrate | Fenofibrate | 79 | 26 |
| Naproxen | Naproxen | 78 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 19 |
| Fluconazole | Fluconazole | 74 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 27 |
| Lorazepam | Lorazepam | 71 | 16 |
| Donepezil Hcl | Donepezil Hcl | 68 | 18 |
| Enalapril Maleate | Enalapril Maleate | 67 | 23 |
| Ezetimibe | Ezetimibe | 66 | 17 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 66 | 45 |
| Mirtazapine | Mirtazapine | 64 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 28 |
| Clonidine Hcl | Clonidine Hcl | 62 | 25 |
| Spironolactone | Spironolactone | 58 | 15 |
| Nystatin | Nystatin | 57 | 26 |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Allopurinol | Allopurinol | 54 | 18 |
| Januvia | Sitagliptin Phosphate | 54 | 12 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 53 | 25 |
| Mupirocin | Mupirocin | 52 | 31 |
| Diclofenac Potassium | Diclofenac Potassium | 51 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 22 |
| Terbinafine Hcl | Terbinafine Hcl | 49 | 23 |
| Ketoconazole | Ketoconazole | 48 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 47 | 19 |
| Linzess | Linaclotide | 46 | 11 |
| Amoxicillin | Amoxicillin | 45 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 13 |
| Atenolol | Atenolol | 43 | 12 |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Azelastine Hcl | Azelastine Hcl | 42 | 24 |
| Cefdinir | Cefdinir | 42 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 14 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 42 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | 12 |
| Lactulose | Lactulose | 33 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Carisoprodol | Carisoprodol | 32 | suppressed |
| Prednisone | Prednisone | 32 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Pregabalin | Pregabalin | 31 | 15 |
| Cilostazol | Cilostazol | 30 | 15 |
| Lidocaine | Lidocaine | 30 | 11 |
| Valsartan | Valsartan | 30 | suppressed |
| Nystop | Nystatin | 28 | 21 |
| Torsemide | Torsemide | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 13 |
| Metronidazole | Metronidazole | 27 | 22 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 27 | 23 |
| Risperidone | Risperidone | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | 11 |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | 13 |
| Diazepam | Diazepam | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | 13 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $711.62 · 34 records | Novo Nordisk Inc | ABRYSVO, AREXVY, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KISUNLA, KRYSTEXXA, MOUNJARO, NEXLETOL, Omnipod, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error